Adverse Drug Reaction Classification System

         

ADR Ontology
ADR Term Myelodysplastic syndrome
ADR ID BADD_A02926
ADR Hierarchy
01      Blood and lymphatic system disorders
01.10      Leukaemias
01.10.04      Myelodysplastic syndromes
01.10.04.001      Myelodysplastic syndrome
16      Neoplasms benign, malignant and unspecified (incl cysts and polyps)
16.01      Leukaemias
16.01.04      Myelodysplastic syndromes
16.01.04.001      Myelodysplastic syndrome
Description A disorder characterized by insufficiently healthy hematapoietic cell production by the bone marrow. [CTCAE] Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA. [MeSH]
MedDRA Code 10028533
MeSH ID D009190; D011289
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE)
Synonym
Marrow dysplasia | Myelodysplasia | Myelodysplastic syndrome | Myelodysplastic syndrome NOS | Myeloid dysplasia | Preleukaemia | Bone marrow dysplasia | Preleukemia | Osteomyelodysplasia | MDS | Myelodysplastic syndrome progression to higher risk | Myelodysplastic syndrome progression | Myelodysplastic Syndromes | Myelodysplastic Syndrome | Syndrome, Myelodysplastic | Syndromes, Myelodysplastic | Dysmyelopoietic Syndromes | Dysmyelopoietic Syndrome | Syndrome, Dysmyelopoietic | Syndromes, Dysmyelopoietic | Hematopoetic Myelodysplasia | Hematopoetic Myelodysplasias | Myelodysplasia, Hematopoetic | Myelodysplasias, Hematopoetic
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D01834Prednisone0.000027%
BADD_D01901Radium--
BADD_D01909Ramipril0.000280%
BADD_D01978Ruxolitinib0.000645%
BADD_D02007Semaxanib--
BADD_D02093Sulfasalazine--
BADD_D02150Temozolomide0.000224%
BADD_D02192Thalidomide0.001615%
BADD_D02203Thiotepa--
BADD_D02246Tolvaptan0.000058%
BADD_D02252Tositumomab--
BADD_D02329Valproic acid--
BADD_D02331Valsartan--
BADD_D02345Venetoclax0.001455%
BADD_D02360Vincristine0.000112%
BADD_D02369Voriconazole0.014521%
BADD_D02370Vorinostat0.000112%
BADD_D02375Water--
BADD_D02392Zoledronic acid0.005726%
BADD_D02412Octreotide0.000279%
BADD_D02442Magnesium oxide0.000182%
BADD_D02443Tiotropium0.000086%
BADD_D02453Midostaurin0.000224%
BADD_D02470Nintedanib0.000280%
BADD_D02480Alectinib0.000112%
BADD_D02482Acalabrutinib0.000112%
BADD_D02485Talazoparib0.000336%
BADD_D02510Rucaparib0.000392%
BADD_D02568Lutetium oxodotreotide lu-177-
The 3th Page    First    Pre   3    Total 3 Pages